Sort   by:  
 Page size 
Polymyxin B (PB) is introduced into the clinic as the last-line therapy against carbapenem-resistant Klebsiella pneumoniae (CRKP). Unfortunately, increased resistance to PB in Klebsiella pneumoniae (K. pneumoniae) has threatened global health. Resistance of K. pneumoniae ...
2022-03-04 | MTBLS4132 | MetaboLights

BACKGROUND AND AIMS: Atherosclerosis, characterized by dysfunction of lipid metabolism and chronic inflammation, is considered as a metabolic disorder as well as a major contributor to cardiovascular diseases. However, metabolic signatures of atherosclerosis have not been well ex...

2024-09-26 | MTBLS9737 | MetaboLights
Sort   by:  
 Page size